BRAF-activated lncRNA predicts gastrointestinal cancer patient prognosis: a meta-analysis
Metrics: PDF 1387 views | HTML 2124 views | ?
Yang-Hua Fan1,*, Min-Hua Ye1,*, Lei Wu1, Miao-Jing Wu1, Shi-Gang Lu1, Xin-Gen Zhu1
1Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, People’s Republic of China
*These authors contributed equally to this work
Xin-Gen Zhu, email: email@example.com
Shi-Gang Lu, email: firstname.lastname@example.org
Keywords: BANCR, long non-coding RNA, gastrointestinal cancer, biomarker, meta-analysis
Received: October 20, 2016 Accepted: December 13, 2016 Published: December 21, 2016
BRAF activated non-coding RNA (BANCR) is often dysregulated in cancer. We performed a meta-analysis to clarify its functions as a prognostic indicator in malignant tumors. We searched the PubMed, Medline, OVID, Cochrane Library, and Web of Science databases to identify BANCR-related studies. Nine original studies and 898 total patients were included in the meta-analysis. Hazard ratios (HR) and 95% confidence intervals (CI) were extracted from the included studies to determine the relationship between BANCR expression and patient overall survival (OS). Odds ratios (OR) were calculated using RevMan 5.3 software to assess associations between BANCR expression and pathological parameters. High BANCR expression correlated with lymph node metastasis (LNM) (OR = 3.41, 95% CI: 1.82–6.37, P = 0.0001), distant metastasis (DM) (OR = 2.98, 95% CI: 1.76–5.07, P < 0.0001), tumor stage (OR = 3.11, 95% CI: 1.89–5.12, Z = 3.25, P < 0.0001), and poor OS (pooled HR = 1.98, 95% CI: 1.20–3.27, P = 0.008) in gastrointestinal (GI) cancer patients, but not in non-GI cancer patients. Our results support the notion that BANCR as a promising prognostic biomarker in Chinese patients with GI cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.